Prediction of Drug Response Using an Ex Vivo Organ Culture (EVOC) on Fresh Human Tumour Samples From Metastatic Patients

Metastatic Cancer Clinical Trial

— CURESPONSE  

Official title:

Prediction of Patient Drug Response Using an Ex Vivo Organ Culture (EVOC) on Fresh Human Tumour Samples From Metastatic Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04599608
• Other study ID #: 20HH6332
• Status: Not yet recruiting
• Start date: February 2021
• Est. completion date: January 2026

Study information

• Verified date: October 2020
• Source: Imperial College London
• Contact: Ayushi J Pabari
• Phone: +44 (0)20 3313 0684
• Email: a.pabari[@]imperial.ac.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The primary objective of this study is to determine how sensitive and specific the Curesponse Ex Vivo Organ Culture (EVOC) model is at predicting a patient's clinical response to a specific cancer therapy.

248 patients from participating UK hospitals will have a biopsy for the development of an Ex-vivo organ culture at the Curesponse Laboratory. Patients will have standard of care anticancer therapy after the biopsy and be followed up for 6 months following their biopsy.

The combined results of the study will show whether the EVOC has potential to be useful for future patients prospectively in determining whether a certain clinical treatment is likely to benefit them.

Description:

This is a A Phase II multi-centre prediction study of the Curesponse Ex Vivo Organ Culture (EVOC) model in patients with suspected or confirmed advanced or metastatic malignancy.

Patients with suspected or confirmed, advanced or metastatic malignancy in whom at least 1 site is amenable for biopsy, and who would be planned to receive systemic anti-cancer therapy, where disease response can be measured by conventional imaging methods will be recruited for this study.

Patients will undergo a research biopsy where up to 6 tissue samples will be collected. Patients will also have the option to provide an additional single blood sample for germline genetic testing. Patients will then attend their hospital clinical to receive standard of care anticancer therapy as discussed with their oncologist.

Concurrently to the patients treatment, the tissue samples will be transported to the Curesponse laboratory for the development of the EVOC. The EVOC will be treated with a range of anticancer therapies, including the same treatment that the patient will be receiving in clinic. The model will predict whether the cancer will respond to the therapy. Additionally, providing the patient consents, the tissue will also undergo tumour gene profiling related to the secondary and exploratory endpoints and objectives.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 248
• Est. completion date: January 2026
• Est. primary completion date: February 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Suspected or confirmed advanced or metastatic cancer

2. Aged > 18 years

3. Life expectancy > 3 months

4. ECOG Performance Status 0-2

5. At least one tumour lesion which is amenable for 16 G biopsy (minimum of 2 cores)

6. Planned to receive standard of care therapy or an experimental treatment as part of a clinical trial following the biopsy

7. Written informed consent and ability to comply with study protocol

8. Measurable disease as per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 by CT or MRI

Exclusion Criteria:

1. Pregnant and/or breastfeeding woman

2. Lesion is non accessible

3. Any other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study

4. Known carrier for acquired immune deficiency syndrome (AIDS)

5. Known carrier for hepatitis B or hepatitis C virus indicating acute or chronic infection

Related Conditions & MeSH terms

• Advanced Cancer
• Metastatic Cancer
• Neoplasm Metastasis

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Imperial College London	Curesponse Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The EVOC to demonstrate a sensitivity and specificity of at least 70% for predicting a patients clinical response to a specific anti-cancer therapy	Comparison of patient's treatment clinical to the EVOC treated with the same therapy.	From biopsy to the end of the patient's final imaging response assessment at Follow up 3.
Primary	Assessment of tumour heterogeneity in relation to treatment response using the EVOC model	Tumour gene profiling on tissue samples obtained at the biopsy	During the biopsy
Primary	Assess variability in cell populations within the EVOC before and after treatment.	FACS and other methods of analysis to analyse the changes in cell population of the EVOC.	From pre-treatment of EVOC up to the end of treatment on the EVOC model.
Primary	Evaluation and characterisation of viable and resistant cancer cells in the EVOC following treatment and assessment of their response to other therapeutic agents.	Following treatment of EVOC, viable/resistant cancer cells to be extracted and harvested, to be further grown for further treatment response assessments in the laboratory.	End of treatment on EVOC model.
Secondary	Comparison of the clinical utility of the EVOC compared to other predictions of response via additional technologies for cancer treatment.	Assessed by genomic profiling where relevant, and the comparison of tumour gene profiling to germline genetic testing.	Biopsy up to end of treatment of EVOC.